Apple Inc.'s stock has struggled to find positive momentum this year, and analysts at Needham & Company don't see major catalysts ahead that can help put shares on a better course.

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094.

Adam Turnquist, a technical strategist at LPL Financial, said the recovery in stock-market breadth is a particularly convincing bullish "tell" suggesting that the market's recovery appears to be on ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

23andMe has said it wants to allow new bids by both parties with a deadline of 12th June, according to a Financial Times ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) announced favorable Phase 3 trial results for itepekimab and entered a significant licensing agreement with Telesis Bio, enhancing its R&D capabilities.

E.L.F. Beauty’s stock is up more than 34% in the last week. The positive performance, primarily driven by an over 23% surge on Thursday, comes after the company announced a $1 billion deal to acquire ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

A rally in Deutsche Boerse shares illustrates how Europe is bridging a value gap with its Wall Street peers, as fiscal ...

Once the Nasdaq delisting on Form 25 becomes effective, 23andMe intends to file a Form 15 to deregister with the SEC. About 23andMe 23andMe is a genetics-led consumer healthcare and biotechnology ...

Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract ...

The S&P 500 slipped 0.4% on Tuesday, May 20, snapping a six-day winning streak as investors' confidence on trade and ...